Kerala Daily

Complement 3 Glomerulopathy Epidemiology Forecast to 2030 By Delveinsight

 Breaking News
  • No posts were found

Complement 3 Glomerulopathy Epidemiology Forecast to 2030 By Delveinsight

July 30
10:36 2020
Complement 3 Glomerulopathy Epidemiology Forecast to 2030 By Delveinsight

(Albany, US) Delveinsight has launched a new report on Complement 3 Glomerulopathy Epidemiology

 DelveInsight’s Complement 3 Glomerulopathy Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Complement 3 glomerulopathy (C3G) was adopted by expert consensus in 2013 to define a group of rare kidneys diseases driven by dysregulation of the complement cascade. It is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4.  The term C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when observed under a microscope. People with DDD generally present at a younger age (childhood or adolescence) compared to people with C3GN (adulthood).  In DDD, C3 deposits are bunched up in one area of the glomeruli and appear thick while in case of C3GN, C3 deposits are more spread out and less thick. Progression to end-stage renal disease (ESRD) has been found in 40% of C3G patients, with no detectable difference between those with C3GN versus DDD. Dysregulation of the complement alternative pathway, driven by acquired and/or genetic defects, plays a pathogenetic role in C3G. However, alternative pathway abnormalities are also found in IC-MPGN (immune-complex-MPGN). The most common acquired drivers of C3G are the C3 nephritic factors (C3NeFs),heterogeneous autoantibodies that stabilize the C3 convertase, C3bBb.

 

 

Request for free sample page:- https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-epidemiology-forecast

 

Complement 3 Glomerulopathy Epidemiology Perspective

The Complement 3 Glomerulopathy (C3G) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Complement 3 Glomerulopathy (C3G) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Complement 3 Glomerulopathy (C3G) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders..

Complement 3 Glomerulopathy Epidemiology

As per the National Organization for Rare Disorders (NORD), C3G affects persons of all ages, although the mean age appears to be lower in DDD patients as compared to C3GN patients. The prevalence of C3G is estimated at 2–3 per 1,000,000 people. The dynamics of C3G market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2020-2030.

 

Key facts of the report

  • The market size of C3G in the seven major markets was found to be USD 40.6 Million in 2017.
  • The United States accounts for the largest market size of C3G, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
  • Among the EU5 countries, Germany had the highest market size with USD 3.6 Million in 2017, while Spain had the lowest market size of C3G with USD 2.2 Million in 2017.
  • The Japan C3G market accounted for USD 3.0 Million in 2017.
  • In the United Kingdom, the total market size of C3G was estimated to be USD 2.9 Million in 2017.

Scope of the Report

  • The report covers the descriptive overview of Complement 3 Glomerulopathy (C3G) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Complement 3 Glomerulopathy (C3G) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Complement 3 Glomerulopathy (C3G) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Complement 3 Glomerulopathy (C3G) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Complement 3 Glomerulopathy (C3G) market

 

Request for free sample page:- https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-epidemiology-forecast

 

Table of content

1. Key Insights 

2. Executive Summary of Complement 3 Glomerulopathy (C3G)

3. Complement 3 Glomerulopathy (C3G): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Why should you buy this report?

  • The Complement 3 Glomerulopathy (C3G) Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Complement 3 Glomerulopathy (C3G) market
  • Quantify patient populations in the global Complement 3 Glomerulopathy (C3G) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Complement 3 Glomerulopathy (C3G) therapeutics in each of the markets covered
  • Understand the magnitude of Complement 3 Glomerulopathy (C3G) population by its epidemiology
  • The Complement 3 Glomerulopathy (C3G) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/